Gadofosveset trisodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for gadofosveset trisodium and what is the scope of freedom to operate?
Gadofosveset trisodium
is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for gadofosveset trisodium
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 16 |
| Clinical Trials: | 6 |
| Patent Applications: | 21 |
| DailyMed Link: | gadofosveset trisodium at DailyMed |
Recent Clinical Trials for gadofosveset trisodium
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Paul Finn | Phase 4 |
| Maastricht University Medical Center | Phase 4 |
| Maastricht University Medical Center |
Anatomical Therapeutic Chemical (ATC) Classes for gadofosveset trisodium
US Patents and Regulatory Information for gadofosveset trisodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for gadofosveset trisodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for gadofosveset trisodium
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| TMC Pharma Services Ltd. | Ablavar (previously Vasovist) | gadofosveset trisodium | EMEA/H/C/000601 This medicinal product is for diagnostic use only.Ablavar is indicated for contrast-enhanced magnetic resonance angiography (CE-MRA) for visualisation of abdominal or limb vessels in adults only, with suspected or known vascular disease. |
Withdrawn | no | no | no | 2005-10-03 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
